Compare BNTC & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNTC | EBS |
|---|---|---|
| Founded | 1995 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 315.4M | 303.3M |
| IPO Year | 2020 | 2006 |
| Metric | BNTC | EBS |
|---|---|---|
| Price | $7.92 | $5.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $23.75 | $10.00 |
| AVG Volume (30 Days) | 154.2K | ★ 946.0K |
| Earning Date | 11-13-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 6.67 | ★ 125.83 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $742,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.89 | $4.36 |
| 52 Week High | $14.39 | $14.06 |
| Indicator | BNTC | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 37.62 | 27.56 |
| Support Level | N/A | $4.36 |
| Resistance Level | $13.87 | $7.18 |
| Average True Range (ATR) | 0.66 | 0.42 |
| MACD | -0.08 | -0.10 |
| Stochastic Oscillator | 5.18 | 3.79 |
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.